GLPG Key Statistics, Chart & Performance
The current stock price of GLPG is 31.48 USD. In the past month the price increased by 1.25%. In the past year, price increased by 17.04%.
GLPG Latest News, Press Relases and Analysis
GLPG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.71B | ||
| AMGN | AMGEN INC | 14.71 | 173.27B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 111.89B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 74.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 846.48 | 57.03B | ||
| INSM | INSMED INC | N/A | 42.45B | ||
| NTRA | NATERA INC | N/A | 33.32B | ||
| BIIB | BIOGEN INC | 10.79 | 26.50B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.11 | 20.58B | ||
| INCY | INCYTE CORP | 15.29 | 19.28B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.17B |
Related stock screener links
About GLPG
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV-SPON ADR
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN 2800 BE
CEO: Onnovan deStolpe
Employees: 704
Phone: 3215342900
GALAPAGOS NV-SPON ADR / GLPG FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
What is the stock price of GALAPAGOS NV-SPON ADR today?
The current stock price of GLPG is 31.48 USD. The price decreased by -0.35% in the last trading session.
Does GLPG stock pay dividends?
GLPG does not pay a dividend.
How is the ChartMill rating for GALAPAGOS NV-SPON ADR?
GLPG has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting GLPG stock to perform?
19 analysts have analysed GLPG and the average price target is 34.5 USD. This implies a price increase of 9.59% is expected in the next year compared to the current price of 31.48.
How many employees does GALAPAGOS NV-SPON ADR have?
GALAPAGOS NV-SPON ADR (GLPG) currently has 704 employees.
What is the market capitalization of GLPG stock?
GALAPAGOS NV-SPON ADR (GLPG) has a market capitalization of 2.07B USD. This makes GLPG a Mid Cap stock.
GLPG Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GLPG. When comparing the yearly performance of all stocks, GLPG turns out to be only a medium performer in the overall market: it outperformed 64.09% of all stocks.
GLPG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLPG. The financial health of GLPG is average, but there are quite some concerns on its profitability.
GLPG Financial Highlights
Over the last trailing twelve months GLPG reported a non-GAAP Earnings per Share(EPS) of -7.72. The EPS decreased by -311.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| Debt/Equity | 0 |
GLPG Forecast & Estimates
19 analysts have analysed GLPG and the average price target is 34.5 USD. This implies a price increase of 9.59% is expected in the next year compared to the current price of 31.48.
For the next year, analysts expect an EPS growth of -541.12% and a revenue growth -3.68% for GLPG